HTG Molecular Diagnostics - About the company
HTG Molecular Diagnostics is a public company based in Tucson (United States), founded in 1997. It operates as a Developer of diagnostics and targeted therapeutics across a variety of disease areas. HTG Molecular Diagnostics has raised $50.7M in funding from investors like SR One, Fletcher Spaght and Merck. The company has 395 active competitors, including 133 funded and 86 that have exited. Its top competitors include companies like MedGenome, Caris Life Sciences and Geneoscopy.
Company Details
Developer of diagnostics and targeted therapeutics across a variety of disease areas. The company is a leading provider of molecular-based technology solutions for gene expression profiling, miRNA, siRNA, and mRNA measurement for translational medicine and diagnostic applications. Their automated HTG Edge platform is designed to quickly and simultaneously profile thousands of clinically relevant molecular targets from samples a fraction of the size required by current technologies. Also offers services (VERI/O Laboratory Services ) such as retrospective sample processing, pilot studies, custom assay development, disease-specific validation studies, and molecular profiling studies
- Website
- htgmolecular.com
- Social
- Email ID
- *****@htgmolecular.com
- Phone Number
- +1 **********
- Registered Address
- 3430 E. Global Loop, Tucson, AZ 85706
Key Metrics
Founded Year
1997
Location
Tucson, United States
Stage
Public
Total Funding
$50.7M in 19 rounds
Latest Funding Round
Ranked
90th among 395 active competitors
Annual Revenue
$1M - $10M as on Dec 31, 2022
Employee Count
30 as on Jun 30, 2026
Exit Details
Public
Legal entities associated with HTG Molecular Diagnostics
HTG Molecular Diagnostics is associated with 2 legal entities given below:
Legal Entity Name | Date of Incorporation | Revenue | Latest Employee Count | Documents |
|---|---|---|---|---|
HTG MOLECULAR DIAGNOSTICS, INC. CIN: 860912294 , United States, Active | Dec 31, 1999 | - | 47 (As on Dec 31, 2022) | - |
HTG MOLECULAR DIAGNOSTICS, INC CIN: 1169987 , United States, Active | Dec 13, 2000 | $1M - $10M (As on Dec 31, 2022) | - | - |
HTG Molecular Diagnostics's IPO details
HTG Molecular Diagnostics got listed on May 08, 2015.
Click here to take a look at HTG Molecular Diagnostics's IPO in detail
Sign up to download HTG Molecular Diagnostics' company profile
HTG Molecular Diagnostics's funding and investors
HTG Molecular Diagnostics has raised a total funding of $50.7M over 19 rounds. Its first funding round was on May 04, 2005. Its latest funding round was a Post IPO round on Jun 25, 2020 for $*****. 1 investor participated in its latest round. HTG Molecular Diagnostics has 13 institutional investors.
Here is the list of recent funding rounds of HTG Molecular Diagnostics:
Filter this list
Filter this listDate of Funding | Funding Amount | Round Name | Post-Money Valuation | Revenue Multiple | Lead Investors | Other Investors |
|---|---|---|---|---|---|---|
Jun 25, 2020 | 8212215 | Post IPO | 3739574 | 8351491 | 3577289 | 3764438 |
Sep 24, 2019 | 5609553 | Post IPO | 3796312 | 6557271 | 8748075 | 1150765 |
Jan 28, 2018 | 7274476 | Post IPO | 7610456 | 3327611 | 9163365 |
Access funding benchmarks and valuations. Sign up today!View details of HTG Molecular Diagnostics's funding rounds and investors
HTG Molecular Diagnostics' founders and board of directors
Founder? Claim ProfileHTG Molecular Diagnostics' employee count trend
HTG Molecular Diagnostics has 30 employees as of Jun 26. Here is HTG Molecular Diagnostics's employee count trend over the years:
Uncover HTG Molecular Diagnostics' growth story! Sign up today!
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
HTG Molecular Diagnostics's Competitors and alternates
Top competitors of HTG Molecular Diagnostics include MedGenome, Caris Life Sciences and Geneoscopy. Here is the list of Top 10 competitors of HTG Molecular Diagnostics, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st | Provider of DNA sequencing, bioinformatics, and multiomics services | $264M | 71/100 | ||
2nd | Caris Life Sciences 1996, Irving (United States), Public | Developer of panomic disease profiling technologies for cancer precision medicine | $1.23B | 70/100 | |
3rd | Geneoscopy 2015, St. Louis (United States), Series C | Developer of non-invasive biomarker tests for colorectal cancer | $219M | 67/100 | |
4th | Intellia Therapeutics 2014, Cambridge (United States), Public | Developer of therapeutics based on CRISPR/Cas9 technology for multiple diseases | $85M | 66/100 | |
5th | Personalis 2011, Menlo Park (United States), Public | Provider of genomic sequencing and diagnosis software for the healthcare industry | $87.3M | 65/100 | |
6th |  Deep Genomics 2014, Toronto (Canada), Series C | AI-powered platform for RNA biology to accelerate genetic therapy discovery | $238M | 63/100 | |
7th | Precipio Diagnostics 1997, New Haven (United States), Public | Provider of cancer diagnostics and second opinion tools | $800K | 63/100 | |
8th |  Adela 2021, San Francisco (United States), Series A | Developer of a platform for detection of cancer | $139M | 62/100 | |
9th | Strata Oncology 2015, Ann Arbor (United States), Series C | Precision oncology company enabling smarter cancer treatment through advanced biomarker algorithms | $139M | 62/100 | |
10th |  UniQure 1998, Amsterdam (Netherlands), Public | Developer of gene-based therapies for patients with genetic or acquired diseases | $111M | 62/100 | |
90th |  HTG Molecular Diagnostics 1997, Tucson (United States), Public | Developer of diagnostics and targeted therapeutics across a variety of disease areas | $50.7M | 45/100 |
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!Looking for more details on HTG Molecular Diagnostics's competitors? Click here to see the top ones
HTG Molecular Diagnostics's Investments and acquisitions
HTG Molecular Diagnostics has made no investments or acquisitions yet.
Reports related to HTG Molecular Diagnostics
Here is the latest report on HTG Molecular Diagnostics's geography:
News related to HTG Molecular Diagnostics
Filter this list•
•
HTG Molecular Diagnostics Files for Chapter 11 BankruptcyGenomeWeb•Jun 06, 2023•HTG Molecular Diagnostics
•
•
•
•
HTG Molecular Diagnostics expects FY22 revenue above consensusSeeking Alpha•Jan 06, 2023•HTG Molecular Diagnostics
•
HTG Molecular stock dips after pricing $10M securities offeringSeeking Alpha•Dec 21, 2022•HTG Molecular Diagnostics
•
•
•
HTG, Datavant and Mathematica team up to battle chronic kidney disease, long COVIDFierce Biotech•Sep 14, 2022•HTG Molecular Diagnostics, Datavant, Mathematica
Get curated news about company updates, funding rounds, M&A deals and others. Sign up today!Are you a Founder ?
FAQs about HTG Molecular Diagnostics
Explore our recently published companies
- Wisdom Square Technologies - New Hyde Park based, 2008 founded, Unfunded company
- Fruverpack - Almoradi based, 1992 founded, Unfunded company
- AERA - Bouxwiller based, 1979 founded, Unfunded company
- Divine Hindu - Ujjain based, 2023 founded, Unfunded company
- Globaldigitalpartner.com - 2013 founded, Unfunded company
- OROK - Bourgoin Jallieu based, 2018 founded, Deadpooled company
